Incyte Corporation (INCY) : On Thursday, The money flowed into the Incyte Corporation (INCY) stock with an uptick to downtick ratio was recorded at 1.15. Transactions worth $14.59 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $12.67 million. The total money flow into the stock was $1.92 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $1.09 million of block transactions on upticks. The total money flow in block trades was $1.09 million. In terms of price action, Incyte Corporation (INCY) traded down $0.35 during the session at $82.21. Compared to the previous days closing, the stock was down only by -0.42%. For the week, the stock is -4.07%, over previous weeks closing.
The stock has recorded a 20-day Moving Average of 2.5% and the 50-Day Moving Average is 3.85%. Shares have dropped -24.78% from its 1 Year high price. On Sep 16, 2015, the shares registered one year high at $133.62 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $81.22 and the 200 Day Moving Average price is recorded at $77.64.
Incyte Corporation (NASDAQ:INCY): The stock opened at $83.31 on Thursday but the bulls could not build on the opening and the stock topped out at $83.80 for the day. The stock traded down to $81.27 during the day, due to lack of any buying support eventually closed down at $82.14 with a loss of -0.51% for the day. The stock had closed at $82.56 on the previous day. The total traded volume was 735,916 shares.
In an insider trading activity, Swain Paula J, officer (EVP, Human Resources) of Incyte Corp, unloaded 13,531 shares at an average price of $76.96 on January 15, 2016. The total amount of the transaction was worth $1,041,346, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f